Investor Presentaiton

The Pharma testing market is both healthy and full of potential Need for big pharma companies to expand new drugs pipelines Rapid technological change & increasing complexity in testing require ongoing investment in technology & expertise eurofins • • • The increasing complexity of clinical trials leads to increasing amounts of diagnostic procedures performed per patent Regulatory bodies (e.g. FDA) are demanding more study data to improve safety New wave of biologics require more testing Clinical trial processes are becoming increasingly rigorous to ensure drug efficacy The spend per drug trial is rapidly increasing Greater trial complexity & size will increase likelihood of using CROS 47

View entire presentation